The Supreme Court on Tuesday questioned the disparity in drug pricing with essential cancer drugs sold to consumers at a whopping ₹27,000 when the price at which it is sold to retailers is only ₹2,700, observing that this amounts to “broad daylight dacoity” and asked the government authorities why they fail to act on this crucial issue